Vaccines of the future: from rational design to clinical development. 17-19 October 2001, Paris, France.
The Institut Pasteur (France) sponsors and organises a series of Euroconferences on important topics in biology, medicine and environmental sciences which facilitate a large exchange of ideas between basic and applied scientists from the Institut Pasteur, other academic institutions, and pharmaceutical companies. This Euroconference focused on the most recent advances currently affecting the way vaccine development is approached. The identification of new target antigens for vaccination purposes is presently facilitated by the availability of genome sequences from a growing number of important pathogens and tumours. The identification of T-cell epitopes and the subsequent optimisation of these target sequences allows the design of vaccines which are significantly improved with respect to their capacity to stimulate cellular immunity. In parallel, various antigen formulations, adjuvants and delivery systems are being developed and tested with the aim of eliciting broad immune responses in humans. These new orientations capitalise on recent major advances in the understanding of the use of therapeutic vaccines and expands on their use from being solely profilactic. Specific issues related to the development of therapeutic vaccines directed against diseases such as cancer or chronic infectious disease were presented.
Silva
Celio L
CL
REDE-TB- Department of Biochemistry and Immunology, School of Medicine of Ribeirāo Preto, University of Sāo Paulo, 14049-900-Avenida dos Bandeirantes 3900, Riberão Preto, Sāo Paulo, Brazil. clsilva@fmrp.usp.br
De Souza
Ana O
AO
D000951:Antigens, Neoplasm / Q000276:immunology; D015658:HIV Infections / Q000517:prevention & control; D006801:Humans; D007114:Immunization / Q000639:trends*; D014376:Tuberculosis / Q000517:prevention & control; D014612:Vaccines / Q000627:therapeutic use*
D000951:Antigens, Neoplasm; D014612:Vaccines